Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Trading Update - Consultation with Bondholders

5 Feb 2026 07:00

RNS Number : 7758R
Ceiba Investments Limited
05 February 2026
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR"). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

CEIBA INVESTMENTS LIMITED

(the "Company")

 

(TICKER: CBA, ISIN: GG00BFMDJH11)

Legal Entity Identifier: 213800XGY151JV5B1E88

 

TRADING UPDATE

CONSULTATION WITH BONDHOLDERS

 

The Board of Directors of CEIBA Investments Limited (the "Company") wishes to provide an update on the severe headwinds that Cuba, and the Company, are facing since the Company's last update provided within its Half-Yearly Report published on 29 September 2025.

 

Since the inauguration of President Donald Trump in 2025, the United States has intensified its hard-line policy towards Cuba, characterized by a strengthened economic embargo, intensified sanctions, and restrictions on travel and financial transactions, aimed at pressuring the Cuban government. More recently, the Trump administration has further intensified its policy by restricting energy supplies by blocking oil supplies from Venezuela and threatening tariffs on any country that provides oil to the island.

 

The Company believes these actions are much more consequential than previous restrictions placed on Cuba by the United States and, unless relaxed, are potentially catastrophic for Cuba's infrastructure and economy.

 

Although at the present time it appears that the Trump administration is seeking a negotiated settlement with the Cuban government, no agreement has yet been reached, and it is not clear whether discussions between the parties are ongoing. 

 

This results in a very high degree of uncertainty regarding the continuing availability of fuel, electricity and other basic inputs necessary for the normal operation of the Cuban economy. Consequently, this has a material impact on the prospects of the Cuban tourism industry in 2026 and therefore on the Company's ability to operate its assets on a profitable basis in the short term.

 

During FY25 and into the current financial year, the operational results and performance of all of the five hotels and the mixed-use retail and office complex in which the Company is invested have remained relatively positive and profitable. Nevertheless, over the period the aggregate income from the Company's operations has been substantially lower than anticipated which, when combined with the projected cash flows expected to be received in Q1 2026, means that the Company does not anticipate being able to satisfy repayment of the full amount of the upcoming €5m second principal tranche (Segment B) plus interest of its existing bond instrument (the "Bond Instrument"), due on 31 March 2026. 

 

In addition, the Company's Board and Management believe that in the present circumstances, owing to the very high degree of uncertainty in the near term, the Company should maintain sufficient cash reserves to safeguard the operations of the Company for a period of up to one year.

 

Consultation with Bondholders

 

During February 2026, in order to avoid a potential event of default under the terms of Bond Instrument, the Company intends to consult with Bondholders with a formal proposal to amend some of the terms of the Bond Instrument, including, inter alia, to: i) extend the term of the Bond Instrument by 12 months by deferring each of the four remaining segments (B, C, D and E) by that additional period; ii) allow the Company to issue new ordinary shares representing up to 10% of current issued shares; and iii) allow the Company to sell part of its assets provided that the proceeds thereof are applied towards the repayment of the Bond Instrument.

 

The Company will provide a further update on the consultation as and when appropriate.

 

About the Company:

 

CEIBA Investments Limited is a listed closed-end fund dedicated to investing in Cuba, with interests in the commercial and tourism real estate sectors. Its interests include holdings in 2,235 hotel rooms of the Melia Habana (Havana), Melia Las Americas, Melia Varadero, Sol Palmeras (Varadero) and Melia Trinidad Península (Trinidad) hotels, and the 56,000m2 Miramar Trade Center office and retail complex in Havana. As at 30 June 2025, the unaudited net asset value of the Company was USD125,700,785 (31 December 2024: USD 129,968,866), which amount took into consideration deferred management fees payable to Aberdeen in the total amount of USD2,503,950 and the indebtedness to Bondholders of €20 million.

 

 

For further information, please contact:

 

Sebastiaan Berger Via NSM Funds Limited

 

Singer Capital Markets Tel: +44 (0)20 7496 3000

James Maxwell / Patrick Weaver (Corporate Finance)

Sam Geatrex (Sales)

 

NSM Funds Limited Tel: +44(0)1481 743030

 

 

 

 

END OF ANNOUNCEMENT

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDDIUGDGLS
12
Date   Source Headline
5th Jun 20268:33 amRNSTrading Update
27th May 20263:39 pmRNSHolding(s) in Company
22nd May 20262:30 pmRNSHolding(s) in Company
20th May 20263:37 pmRNSHolding(s) in Company
19th May 20261:07 pmRNSHolding(s) in Company
15th May 202612:40 pmRNSDirector/PDMR Shareholding
12th May 20267:00 amRNSIssue of Equity
30th Apr 20267:00 amRNSAnnual Financial Report
14th Apr 20264:46 pmRNSResult of EGM
1st Apr 202611:21 amRNSFurther re Second Amendment of Bond Instrument
27th Feb 20265:14 pmRNSFurther re Second Amendment of Bond Instrument
27th Feb 20262:26 pmRNSDirectorate change
13th Feb 20265:13 pmRNSStatement re Second Amendment of Bond Instrument
13th Feb 20263:20 pmRNSDirector Declaration
12th Feb 20265:32 pmRNSChange of Auditor
5th Feb 20267:00 amRNSTrading Update - Consultation with Bondholders
26th Jan 20263:36 pmRNSDirector/PDMR Shareholding
23rd Dec 20251:39 pmRNSNet Asset Value(s)
4th Dec 20253:25 pmRNSAppointment of Senior Independent Director
2nd Oct 20252:48 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSHalf-year Report
12th Sep 20253:16 pmRNSDirectorate Change
8th Jul 20257:00 amRNSTrading Update - Payment to Bondholders
4th Jul 202512:49 pmRNSDirectorate Change
3rd Jul 20253:14 pmRNSResult of AGM
1st Jul 20251:35 pmRNSNet Asset Value(s)
30th Apr 20257:00 amRNSAnnual Financial Report
28th Apr 202510:26 amRNSDirectorate Change
3rd Feb 20257:00 amRNSStatement re Amendment of Bond Instrument
13th Jan 20255:51 pmRNSStatement re Amendment of Bond Instrument
11th Dec 20241:31 pmRNSNet Asset Value(s)
7th Oct 202410:55 amRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSStatement re Update from the Chairman
27th Sep 20247:00 amRNSHalf-year Report to 30 June 2024
13th Aug 20248:36 amRNSDirectorate Change
20th Jun 20243:09 pmRNSDirector/PDMR Shareholding
20th Jun 20247:00 amRNSNet Asset Value(s)
18th Jun 20244:53 pmRNSResult of AGM
30th Apr 20247:00 amRNSAnnual Financial Report
25th Mar 202411:03 amRNSDirectorate Change
17th Jan 20247:00 amRNSInvestment Update
27th Dec 20239:17 amRNSNet Asset Value(s)
18th Dec 20238:54 amRNSDirector/PDMR Shareholding
3rd Nov 202310:36 amRNSHolding(s) in Company
1st Nov 20239:05 amRNSDirector/PDMR Shareholding
27th Oct 202311:11 amRNSDirector/PDMR Shareholding
16th Oct 20238:37 amRNSAppointment of Non-Executive Director
12th Oct 20234:26 pmRNSDirector/PDMR Shareholding
5th Oct 202310:24 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.